Numerous previous studies have suggested that FCGR3B may be a risk factor for a range of autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis (28).The exact rationale for the role of FCGR3B in the treatment of CC is unclear. This evidence concerns the gene FCGR3B and systemic lupus erythematosus.